{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:20:54Z","timestamp":1780575654241,"version":"3.54.1"},"reference-count":66,"publisher":"Bentham Science Publishers Ltd.","issue":"10","funder":[{"DOI":"10.13039\/501100010256","name":"Science and Technology Program of Guangzhou","doi-asserted-by":"publisher","award":["202206060005"],"award-info":[{"award-number":["202206060005"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Science and Technology Program of Guangzhou","doi-asserted-by":"publisher","award":["202201010093"],"award-info":[{"award-number":["202201010093"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Science and Technology Program of Guangzhou","doi-asserted-by":"publisher","award":["SL2022A03J01489"],"award-info":[{"award-number":["SL2022A03J01489"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation Outstanding Youth Project","doi-asserted-by":"publisher","award":["2021B1515020064"],"award-info":[{"award-number":["2021B1515020064"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009330","name":"Medical Science and Technology Research Foundation of Guangdong","doi-asserted-by":"publisher","award":["A2023224"],"award-info":[{"award-number":["A2023224"]}],"id":[{"id":"10.13039\/501100009330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health Science and Technology Program of Guangzhou","award":["20231A010036"],"award-info":[{"award-number":["20231A010036"]}]},{"name":"Scientific research project of traditional Chinese medicine of Guangdong","award":["20211306"],"award-info":[{"award-number":["20211306"]}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>It has been hypothesized that smoking is associated with the severity of negative\nsymptoms. Until now, no studies have investigated whether the impact of smoking on negative\nsymptoms is dependent on antioxidants. This study was designed to evaluate the effect of smoking on\ntherapeutic response and total antioxidants capacity (TAOC) in antipsychotic-na\u00efve first-episode\n(ANFE) patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The severity of the patient\u2019s symptoms was assessed using the Positive and Negative\nSyndrome Scale (PANSS). A total of 237 ANFE patients were recruited and treated with risperidone\n(oral tablets, 4-6 mg\/day twice a day) for 12 weeks. PANSS was assessed at baseline and a 12-week\nfollow-up. Plasma TAOC levels were also assayed at baseline and week 12.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Relative to nonsmokers with ANFE SZ, smokers had higher PANSS negative subscores.\nThere was no significant difference in TAOC changes after 12 weeks of treatment with risperidone between\nsmokers and non-smokers. However, we found greater improvement in negative symptoms in\nsmokers compared to non-smokers. Further analysis in smokers with SZ demonstrated that improvements\nin negative symptoms were not associated with changes in TAOC.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Our study suggested that smoking affected the severity of baseline negative symptoms\nand further contributed to their reduction after risperidone treatment. However, improvement in negative\nsymptoms was not dependent on the changes in TAOC.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x22666231019105328","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T10:24:27Z","timestamp":1697711067000},"page":"1733-1741","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Smoking, Symptoms Improvement, and Total Antioxidant Capacity in\nPatients with Drug-naive First-episode Schizophrenia: A Prospective\nCohort Study"],"prefix":"10.2174","volume":"22","author":[{"given":"Zhiyong","family":"Gao","sequence":"first","affiliation":[{"name":"The Affiliated Kangning Hospital of Wenzhou Medical University Zhejiang Provincial Clinical Research Center for\nMental Disorder, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihong","family":"Xiu","sequence":"additional","affiliation":[{"name":"Peking University Huilongguan Clinical Medical School, Beijing Huilongguan\nHospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Liu","sequence":"additional","affiliation":[{"name":"The Affiliated Kangning Hospital of Wenzhou Medical University Zhejiang Provincial Clinical Research Center for\nMental Disorder, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengchun","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University,\nGuangzhou, China"},{"name":"Department of Biomedical Engineering, Guangzhou Medical University, Guangzhou, China"},{"name":"Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou,\nChina"},{"name":"Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou,\nChina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University,\nGuangzhou, China"},{"name":"Department of Biomedical Engineering, Guangzhou Medical University, Guangzhou, China"},{"name":"Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders, Guangzhou,\nChina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"109673","DOI":"10.1016\/j.pnpbp.2019.109673","volume":"95","author":"Fang X.","year":"2019","unstructured":"Fang X.; Chen Y.; Wang Y.; Ren J.; Zhang C.; Depressive symptoms in schizophrenia patients: A possible relationship between SIRT1 and BDNF. Prog Neuropsychopharmacol Biol Psychiatry  2019,95,109673","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.psychres.2018.11.051","volume":"271","author":"Fang X.","year":"2019","unstructured":"Fang X.; Chen Y.; Wang Y.; Zhang C.; Identification of risk factors for suicidal ideation in patients with schizophrenia. Psychiatry Res  2019,271,195-199","journal-title":"Psychiatry Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/cercor\/bhaa208","volume":"31","author":"Xiu M.H.","year":"2021","unstructured":"Xiu M.H.; Lang X.; Chen D.C.; Cao B.; Kosten T.R.; Cho R.Y.; Shi H.; Wei C.W.; Wu A.S.; Zhang X.Y.; Cognitive deficits and clinical symptoms with hippocampal subfields in first-episode and never-treated patients with Schizophrenia. Cereb Cortex  2021,31(1),89-96","journal-title":"Cereb Cortex"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/schbul\/sbaa062","volume":"46","author":"Xiu M.H.","year":"2020","unstructured":"Xiu M.H.; Li Z.; Chen D.C.; Chen S.; Curbo M.E.; Wu H.E.; Tong Y.S.; Tan S.P.; Zhang X.Y.; Interrelationships between BDNF, superoxide dismutase, and cognitive impairment in drug-naive first-episode patients with Schizophrenia. Schizophr Bull  2020,46(6),1498-1510","journal-title":"Schizophr Bull"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"216","DOI":"10.24869\/spsih.2018.216","volume":"30","author":"\u0160agud M.","year":"2018","unstructured":"\u0160agud M.; Vuksan-\u0106usa B.; Jak\u0161i\u0107 N.; Mihaljevi\u0107-Pele\u0161 A.; Rojni\u0107 K.M.; Pivac N.; Smoking in Schizophrenia: An updated review. Psychiatr Danub  2018,30(Suppl. 4),216-223","journal-title":"Psychiatr Danub"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/7698030","volume":"2021","author":"Ding J.B.","year":"2021","unstructured":"Ding J.B.; Hu K.; Cigarette smoking and schizophrenia: Etiology, clinical, pharmacological, and treatment implications. Schizophr Res Treatment  2021,2021,1-8","journal-title":"Schizophr Res Treatment"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nrn2849","volume":"11","author":"Changeux J.P.","year":"2010","unstructured":"Changeux J.P.; Nicotine addiction and nicotinic receptors: Lessons from genetically modified mice. Nat Rev Neurosci  2010,11(6),389-401","journal-title":"Nat Rev Neurosci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.neubiorev.2009.07.013","volume":"34","author":"Dome P.","year":"2010","unstructured":"Dome P.; Lazary J.; Kalapos M.P.; Rihmer Z.; Smoking, nicotine and neuropsychiatric disorders. Neurosci Biobehav Rev  2010,34(3),295-342","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40779-022-00420-0","volume":"9","author":"Zhu M.H.","year":"2022","unstructured":"Zhu M.H.; Liu Z.J.; Hu Q.Y.; Yang J.Y.; Jin Y.; Zhu N.; Huang Y.; Shi D.H.; Liu M.J.; Tan H.Y.; Zhao L.; Lv Q.Y.; Yi Z.H.; Wu F.C.; Li Z.Z.; Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: A 12-week randomized, double-blind, placebo-controlled trial. Mil Med Res  2022,9(1),59","journal-title":"Mil Med Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1176\/ajp.155.7.974","volume":"155","author":"Addington J.","year":"1998","unstructured":"Addington J.; el-Guebaly N.; Campbell W.; Hodgins D.C.; Addington D.; Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry  1998,155(7),974-975","journal-title":"Am J Psychiatry"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3109\/00207459309000574","volume":"70","author":"Sandyk R.","year":"1993","unstructured":"Sandyk R.; Cigarette smoking: effects on cognitive functions and drug-induced parkinsonism in chronic schizophrenia. Int J Neurosci  1993,70(3-4),193-197","journal-title":"Int J Neurosci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0306-4603(97)00028-2","volume":"23","author":"Taiminen T.J.","year":"1998","unstructured":"Taiminen T.J.; Salokangas R.K.R.; Saarij&#xE4;rvi S.; Niemi H.; Lehto H.; Ahola V.; Syv&#xE4;lahti E.; Smoking and cognitive deficits in schizophrenia: A pilot study. Addict Behav  1998,23(2),263-266","journal-title":"Addict Behav"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/S0893-133X(02)00372-X","volume":"27","author":"D&#xE9;patie L.","year":"2002","unstructured":"D&#xE9;patie L.; O\u2019Driscoll G.A.; Holahan A.L.; Atkinson V.; Thavundayil J.X.; Kin N.N.; Lal S.; Nicotine and behavioral markers of risk for schizophrenia: A double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology  2002,27(6),1056-1070","journal-title":"Neuropsychopharmacology"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.addbeh.2004.03.009","volume":"29","author":"Williams J.M.","year":"2004","unstructured":"Williams J.M.; Ziedonis D.; Addressing tobacco among individuals with a mental illness or an addiction. Addict Behav  2004,29(6),1067-1083","journal-title":"Addict Behav"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.schres.2007.11.027","volume":"100","author":"Barr A.M.","year":"2008","unstructured":"Barr A.M.; Procyshyn R.M.; Hui P.; Johnson J.L.; Honer W.G.; Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment. Schizophr Res  2008,100(1-3),252-260","journal-title":"Schizophr Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1176\/ajp.149.9.1189","volume":"149","author":"Goff D.C.","year":"1992","unstructured":"Goff D.C.; Henderson D.C.; Amico E.; Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. Am J Psychiatry  1992,149(9),1189-1194","journal-title":"Am J Psychiatry"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"105269","DOI":"10.1016\/j.neuint.2021.105269","volume":"153","author":"Cecerska-Hery\u0107 E.","year":"2022","unstructured":"Cecerska-Hery\u0107 E.; Polikowska A.; Serwin N.; Roszak M.; Grygorcewicz B.; Hery\u0107 R.; Michalczyk A.; Do\u0142\u0119gowska B.; Importance of oxidative stress in the pathogenesis, diagnosis, and monitoring of patients with neuropsychiatric disorders, a review. Neurochem Int  2022,153,105269","journal-title":"Neurochem Int"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"703452","DOI":"10.3389\/fpsyt.2021.703452","volume":"12","author":"Murray A.J.","year":"2021","unstructured":"Murray A.J.; Rogers J.C.; Katshu M.Z.U.H.; Liddle P.F.; Upthegrove R.; Oxidative stress and the pathophysiology and symptom profile of schizophrenia spectrum disorders. Front Psychiatry  2021,12,703452","journal-title":"Front Psychiatry"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0304-3835(97)04610-7","volume":"113","author":"Kim K.B.","year":"1997","unstructured":"Kim K.B.; Lee B.M.; Oxidative stress to DNA, protein, and antioxidant enzymes (superoxide dismutase and catalase) in rats treated with benzo(a)pyrene. Cancer Lett  1997,113(1-2),205-212","journal-title":"Cancer Lett"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1089\/ars.2010.3603","volume":"15","author":"Yao J.K.","year":"2011","unstructured":"Yao J.K.; Keshavan M.S.; Antioxidants, redox signaling, and pathophysiology in schizophrenia: An integrative view. Antioxid Redox Signal  2011,15(7),2011-2035","journal-title":"Antioxid Redox Signal"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.pnpbp.2013.02.015","volume":"46","author":"Wu J.Q.","year":"2013","unstructured":"Wu J.Q.; Kosten T.R.; Zhang X.Y.; Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry  2013,46,200-206","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1164\/ajrccm.160.supplement_1.15","volume":"160","year":"1999","unstructured":"W.; Rahman, I. Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease. Am J Respir Crit Care Med MacNEE 1999,160(5 Pt 2),S58-S65","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.2174\/1570159X19666210920090547","volume":"20","author":"Liu H.","year":"2022","unstructured":"Liu H.; Yu R.; Gao Y.; Li X.; Guan X.; Thomas K.; Xiu M.; Zhang X.; Antioxidant enzymes and weight gain in drug-naive first episode schizophrenia patients treated with risperidone for 12 weeks: A prospective longitudinal study. Curr Neuropharmacol  2022,20(9),1774-1782","journal-title":"Curr Neuropharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1007\/s13311-021-01036-3","volume":"18","author":"Li X.R.","year":"2021","unstructured":"Li X.R.; Xiu M.H.; Guan X.N.; Wang Y.C.; Wang J.; Leung E.; Zhang X.Y.; Altered antioxidant defenses in drug-naive first episode patients with schizophrenia are associated with poor treatment response to risperidone: 12-week results from a prospective longitudinal study. Neurotherapeutics  2021,18(2),1316-1324","journal-title":"Neurotherapeutics"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJM199505043321804","volume":"332","author":"Morrow J.D.","year":"1995","unstructured":"Morrow J.D.; Frei B.; Longmire A.W.; Gaziano J.M.; Lynch S.M.; Shyr Y.; Strauss W.E.; Oates J.A.; Roberts L.J.; II Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med  1995,332(18),1198-1203","journal-title":"N Engl J Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1164\/ajrccm.162.3.2001063","volume":"162","author":"Montuschi P.","year":"2000","unstructured":"Montuschi P.; Collins J.; Ciabattoni G.; Lazzeri N.; Corradi M.; Kharitonov S.A.; Barnes P.J.; Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med  2000,162(3),1175-1177","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"303S","DOI":"10.1378\/chest.117.5_suppl_1.303S-a","volume":"117","author":"MacNee W.","year":"2000","unstructured":"MacNee W.; Oxidants\/Antioxidants and COPD. Chest  2000,117(5)(Suppl. 1),303S-317S","journal-title":"Chest"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.pharmthera.2005.10.015","volume":"111","author":"Kirkham P.","year":"2006","unstructured":"Kirkham P.; Rahman I.; Oxidative stress in asthma and COPD: Antioxidants as a therapeutic strategy. Pharmacol Ther  2006,111(2),476-494","journal-title":"Pharmacol Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1161\/01.CIR.101.19.2252","volume":"101","author":"James R.W.","year":"2000","unstructured":"James R.W.; Leviev I.; Righetti A.; Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation  2000,101(19),2252-2257","journal-title":"Circulation"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/jop.12495","volume":"46","author":"Ahmadi-Motamayel F.","year":"2017","unstructured":"Ahmadi-Motamayel F.; Falsafi P.; Goodarzi M.T.; Poorolajal J.; Evaluation of salivary catalase, vitamin C, and alpha-amylase in smokers and non-smokers: A retrospective cohort study. J Oral Pathol Med  2017,46(5),377-380","journal-title":"J Oral Pathol Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cca.2006.08.028","volume":"377","author":"Northrop-Clewes C.A.","year":"2007","unstructured":"Northrop-Clewes C.A.; Thurnham D.I.; Monitoring micronutrients in cigarette smokers. Clin Chim Acta  2007,377(1-2),14-38","journal-title":"Clin Chim Acta"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1600-0765.2006.00889.x","volume":"41","author":"Garg N.","year":"2006","unstructured":"Garg N.; Singh R.; Dixit J.; Jain A.; Tewari V.; Levels of lipid peroxides and antioxidants in smokers and nonsmokers. J Periodontal Res  2006,41(5),405-410","journal-title":"J Periodontal Res"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1741-2358.2006.00077.x","volume":"23","author":"Kanehira T.","year":"2006","unstructured":"Kanehira T.; Shibata K.; Kashiwazaki H.; Inoue N.; Morita M.; Comparison of antioxidant enzymes in saliva of elderly smokers and non-smokers. Gerodontology  2006,23(1),38-42","journal-title":"Gerodontology"},{"key":"ref=34","first-page":"607","volume":"34","author":"Abdolsamadi H.R.","year":"2011","unstructured":"Abdolsamadi H.R.; Goodarzi M.T.; Mortazavi H.; Robati M.; Ahmadi-Motemaye F.; Comparison of salivary antioxidants in healthy smoking and non-smoking men. Chang Gung Med J  2011,34(6),607-611","journal-title":"Chang Gung Med J"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2174\/1386207322666190806123616","volume":"22","author":"Ahmadi-Motamayel F.","year":"2019","unstructured":"Ahmadi-Motamayel F.; Falsafi P.; Abolsamadi H.; Goodarzi M.T.; Poorolajal J.; Evaluation of salivary antioxidants and oxidative stress markers in male smokers. Comb Chem High Throughput Screen  2019,22(7),496-501","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.9758\/cpn.2017.15.1.40","volume":"15","year":"2017","unstructured":"Evaluation of oxidative status in patients treated with electroconvulsive therapy. Clin Psychopharmacol Neurosci &#x15E;enyurt, M.; Aybek, H.; Herken, H.; Kaptanoglu, B.; Korkmaz, A 2017,15(1),40-46","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.2174\/1570159X19666211111123918","volume":"20","author":"Liu H.","year":"2022","unstructured":"Liu H.; Liu H.; Jiang S.; Su L.; Lu Y.; Chen Z.; Li X.; Li X.; Wang X.; Xiu M.; Zhang X.; Sex-specific association between antioxidant defense system and therapeutic response to risperidone in schizophrenia: A prospective longitudinal study. Curr Neuropharmacol  2022,20(9),1793-1803","journal-title":"Curr Neuropharmacol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000239684","volume":"60","author":"Virit O.","year":"2009","unstructured":"Virit O.; Altindag A.; Yumru M.; Dalkilic A.; Savas H.A.; Selek S.; Erel O.; Herken H.; A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology  2009,60(2),87-93","journal-title":"Neuropsychobiology"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.pnpbp.2011.03.001","volume":"35","author":"Li X.F.","year":"2011","unstructured":"Li X.F.; Zheng Y.L.; Xiu M.H.; Chen D.C.; Kosten T.R.; Zhang X.Y.; Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry  2011,35(4),1064-1067","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00406-015-0596-y","volume":"265","author":"M&#xF6;ller H.J.","year":"2015","unstructured":"M&#xF6;ller H.J.; Czobor P.; Pharmacological treatment of negative symptoms in schizophrenia. Eur Arch Psychiatry Clin Neurosci  2015,265(7),567-578","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000202823","volume":"59","author":"Al-chalabi B.M.","year":"2009","unstructured":"Al-chalabi B.M.; Thanoon I.A.J.; Ahmed F.A.; Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients. Neuropsychobiology  2009,59(1),8-11","journal-title":"Neuropsychobiology"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pharmthera.2018.06.012","volume":"192","author":"Aringhieri S.","year":"2018","unstructured":"Aringhieri S.; Carli M.; Kolachalam S.; Verdesca V.; Cini E.; Rossi M.; McCormick P.J.; Corsini G.U.; Maggio R.; Scarselli M.; Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. Pharmacol Ther  2018,192,20-41","journal-title":"Pharmacol Ther"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1744-859X-9-27","volume":"9","author":"Shiina A.","year":"2010","unstructured":"Shiina A.; Shirayama Y.; Niitsu T.; Hashimoto T.; Yoshida T.; Hasegawa T.; Haraguchi T.; Kanahara N.; Shiraishi T.; Fujisaki M.; Fukami G.; Nakazato M.; Iyo M.; Hashimoto K.; A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry  2010,9(1),27","journal-title":"Ann Gen Psychiatry"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00228-006-0209-9","volume":"62","author":"Haslemo T.","year":"2006","unstructured":"Haslemo T.; Eikeseth P.H.; Tanum L.; Molden E.; Refsum H.; The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol  2006,62(12),1049-1053","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.schres.2016.12.016","volume":"185","author":"Schoretsanitis G.","year":"2017","unstructured":"Schoretsanitis G.; Haen E.; Stegmann B.; Hiemke C.; Gr&#xFC;nder G.; Paulzen M.; Effect of smoking on risperidone pharmacokinetics \u2013 A multifactorial approach to better predict the influence on drug metabolism. Schizophr Res  2017,185,51-57","journal-title":"Schizophr Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"e36563","DOI":"10.1371\/journal.pone.0036563","volume":"7","author":"Zhang X.Y.","year":"2012","unstructured":"Zhang X.Y.; Chen D.C.; Xiu M.H.; Haile C.N.; Sun H.; Lu L.; Kosten T.A.; Kosten T.R.; Cigarette smoking and cognitive function in Chinese male schizophrenia: A case-control study. PLoS One  2012,7(5),e36563","journal-title":"PLoS One"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.schres.2015.06.022","volume":"176","author":"Koga M.","year":"2016","unstructured":"Koga M.; Serritella A.V.; Sawa A.; Sedlak T.W.; Implications for reactive oxygen species in schizophrenia pathogenesis. Schizophr Res  2016,176(1),52-71","journal-title":"Schizophr Res"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3390\/antiox11040646","volume":"11","author":"Wang K.","year":"2022","unstructured":"Wang K.; Xiu M.; Su X.; Wu F.; Zhang X.; Association between changes in total antioxidant levels and clinical symptom improvement in patients with antipsychotic-na&#xEF;ve first-episode schizophrenia after 3 months of risperidone monotherapy. Antioxidants (Basel)  2022,11(4),646","journal-title":"Antioxidants (Basel)"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1177\/0004867412449876","volume":"46","author":"Cooper J.","year":"2012","unstructured":"Cooper J.; Mancuso S.G.; Borland R.; Slade T.; Galletly C.; Castle D.; Tobacco smoking among people living with a psychotic illness: The second Australian survey of psychosis. Aust N Z J Psychiatry  2012,46(9),851-863","journal-title":"Aust N Z J Psychiatry"},{"key":"ref=50","first-page":"7","volume":"29","year":"2019","unstructured":"Ischemia-modified albumin: A unique marker of global metabolic risk in schizophrenia and mood disorders. Psychiatry and Clinical Psychopharmacology  2019,29(2),7","journal-title":"Psychiatry and Clinical Psychopharmacology"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.schres.2013.02.001","volume":"146","author":"Ballesteros A.","year":"2013","unstructured":"Ballesteros A.; Jiang P.; Summerfelt A.; Du X.; Chiappelli J.; O\u2019Donnell P.; Kochunov P.; Hong L.E.; No evidence of exogenous origin for the abnormal glutathione redox state in schizophrenia. Schizophr Res  2013,146(1-3),184-189","journal-title":"Schizophr Res"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/1465-9921-12-133","volume":"12","author":"Gould N.S.","year":"2011","unstructured":"Gould N.S.; Min E.; Gauthier S.; Martin R.J.; Day B.J.; Lung glutathione adaptive responses to cigarette smoke exposure. Respir Res  2011,12(1),133","journal-title":"Respir Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/sj.npp.1301317","volume":"32","author":"Zhang X.Y.","year":"2007","unstructured":"Zhang X.Y.; Tan Y.L.; Zhou D.F.; Haile C.N.; Wu G.Y.; Cao L.Y.; Kosten T.A.R.; Kosten T.; Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia. Neuropsychopharmacology  2007,32(9),2020-2024","journal-title":"Neuropsychopharmacology"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1748-1716.1986.tb07988.x","volume":"128","author":"Grenhoff J.","year":"1986","unstructured":"Grenhoff J.; Aston-Jones G.; Svensson T.H.; Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol Scand  1986,128(3),351-358","journal-title":"Acta Physiol Scand"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/00005053-199507000-00008","volume":"183","author":"Hall R.G.","year":"1995","unstructured":"Hall R.G.; Duhamel M.; McClanahan R.; Miles G.; Nason C.; Rosen S.; Schiller P.; Tao-Yonenaga L.; Hall S.M.; Level of functioning, severity of illness, and smoking status among chronic psychiatric patients. J Nerv Ment Dis  1995,183(7),468-471","journal-title":"J Nerv Ment Dis"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"6","DOI":"10.20882\/adicciones.724","volume":"29","author":"Al-Halab&#xED; S.","year":"2016","unstructured":"Al-Halab&#xED; S.; Fern&#xE1;ndez-Artamendi S.; D&#xED;az-Mesa E.M.; Garc&#xED;a-&#xC1;lvarez L.; Fl&#xF3;rez G.; Mart&#xED;nez-Santamar&#xED;a E.; Arrojo M.; Saiz P.A.; Garc&#xED;a-Portilla M.P.; Bobes J.; Tobacco and cognitive performance in schizophrenia patients: the design of the COGNICO study. Adicciones  2016,29(1),6-12","journal-title":"Adicciones"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1590\/0104-1169.3549.2468","volume":"22","author":"Oliveira R.M.","year":"2014","unstructured":"Oliveira R.M.; Siqueira J&#xFA;nior A.C.; Santos J.L.F.; Furegato A.R.F.; Nicotine dependence in the mental disorders, relationship with clinical indicators, and the meaning for the user. Rev Lat Am Enfermagem  2014,22(4),685-692","journal-title":"Rev Lat Am Enfermagem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/1098-2396(200010)38:1<10:AID-SYN2>3.0.CO;2-T","volume":"38","author":"Drew A.E.","year":"2000","unstructured":"Drew A.E.; Derbez A.E.; Werling L.L.; Nicotinic receptor-mediated regulation of dopamine transporter activity in rat prefrontal cortex. Synapse  2000,38(1),10-16","journal-title":"Synapse"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1176\/ajp.150.4.546","volume":"150","author":"Glassman A.H.","year":"1993","unstructured":"Glassman A.H.; Cigarette smoking: Implications for psychiatric illness. Am J Psychiatry  1993,150(4),546-553","journal-title":"Am J Psychiatry"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0166-4328(00)00204-7","volume":"113","author":"Nomikos G.G.","year":"2000","unstructured":"Nomikos G.G.; Schilstr&#xF6;m B.; Hildebrand B.E.; Panagis G.; Grenhoff J.; Svensson T.H.; Role of &#x3B1;7 nicotinic receptors in nicotine dependence and implications for psychiatric illness. Behav Brain Res  2000,113(1-2),97-103","journal-title":"Behav Brain Res"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/00005053-200209000-00005","volume":"190","author":"Patkar A.A.","year":"2002","unstructured":"Patkar A.A.; Gopalakrishnan R.; Lundy A.; Leone F.T.; Certa K.M.; Weinstein S.P.; Relationship between tobacco smoking and positive and negative symptoms in schizophrenia. J Nerv Ment Dis  2002,190(9),604-610","journal-title":"J Nerv Ment Dis"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0920-9964(92)90024-Y","volume":"8","author":"Lohr J.","year":"1992","unstructured":"Lohr J.; Flynn K.; Smoking and schizophrenia. Schizophr Res  1992,8(2),93-102","journal-title":"Schizophr Res"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1192\/bjp.186.3.215","volume":"186","author":"Aguilar M.C.","year":"2005","unstructured":"Aguilar M.C.; Gurpegui M.; Diaz F.J.; De Leon J.; Nicotine dependence and symptoms in schizophrenia. Br J Psychiatry  2005,186(3),215-221","journal-title":"Br J Psychiatry"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/10550490601184415","volume":"16","author":"Dixon L.","year":"2007","unstructured":"Dixon L.; Medoff D.R.; Wohlheiter K.; Dixon L.; Medoff D.R.; Wohlheiter K.; DiClemente C.; Goldberg R.; Kreyenbuhl J.; Adams C.; Lucksted A.; Davin C.; Correlates of severity of smoking among persons with severe mental illness. Am J Addict  2007,16(2),101-110","journal-title":"Am J Addict"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/j.1440-1614.2006.01841.x","volume":"40","author":"Barnes M.","year":"2006","unstructured":"Barnes M.; Lawford B.R.; Burton S.C.; Heslop K.R.; Noble E.P.; Hausdorf K.; Young R.M.; Smoking and schizophrenia: Is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use? Aust N Z J Psychiatry  2006,40(6-7),575-580","journal-title":"Aust N Z J Psychiatry"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1192\/bjp.bp.111.107953","volume":"201","author":"Krishnadas R.","year":"2012","unstructured":"Krishnadas R.; Jauhar S.; Telfer S.; Shivashankar S.; McCreadie R.G.; Nicotine dependence and illness severity in schizophrenia. Br J Psychiatry  2012,201(4),306-312","journal-title":"Br J Psychiatry"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X22666231019105328","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/222383\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X22666231019105328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T13:31:37Z","timestamp":1715952697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/222383\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":66,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x22666231019105328","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}